News

In an interview with ACT editor Andy Studna at SCOPE, Corrigan discusses what YPrime is doing to address challenges in clinical trials and results from the company's recently released eCOA report.

It is crucial throughout the clinical trials space to understand the challenges and triumphs of DEI.

Partnership comes amid two promising Phase III trial results for non-opioid, non-addictive medication for fibromyalgia.

Results from the randomized, multicenter, open-label, Phase III FLAURA 2 trial show Tagrisso plus chemotherapy delayed disease progression by nearly nine additional months in adults with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

Amtagvi (lifileucel) is a personalized, one-time therapeutic option for adult patients with unresectable or metastatic melanoma who received prior treatment with a PD-1 antibody, and in patients who are BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.

In clinical trials, Xolair was found to significantly increase the amount of peanuts, milk, egg, and cashew that it takes to trigger an allergic reaction in participants with food allergies.

Single-arm, open-label, multicenter, non-randomized, multicohort Phase II VISION trial (NCT02864992) of Tepmetko (tepotinib) for metastatic non–small cell lung cancer shows favorable objective response rate.

A recent study showed that a multimodal machine learning approach accelerated the time in which investigators could determine the efficacy of sertraline treatment in major depressive disorder

Many companies have implemented new technologies and are adopting clinical trial models that are more patient-centric.

The MightySat Fingertip Pulse Oximeter is reportedly the first pulse oximeter available without a prescription.

Device designed to address tricuspid regurgitation through a vein in the leg.

There were no safety or efficacy issues identified in the FDA's complete response letter for Lymphir, with no additional trials required.

In clinical trials, patients administered Aurlumyn monotherapy experienced a significantly reduced risk of the need for amputation associated with severe frostbite.

Trials of Augtyro are ongoing for this tumor-agnostic indication, which could provide a durable treatment option for patients with NTRK-positive disease.

In an interview with ACT editor Andy Studna at SCOPE, Deyle, VP & GM, Clinical Research, Flatiron Health discusses real-world evidence in clinical trials.

The Onivyde combination was evaluated in the open-label, multicenter, randomized Phase III NAPOLI 3 trial, showing significantly improved overall survival in patients with metastatic pancreatic adenocarcinoma.

The drug development process, beginning with preclinical research up to when the product goes to market, requires time, risk, and high costs.

In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.

In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.

In an interview with ACT editor Andy Studna at SCOPE, Morahan, senior director, clinical data analytics, IQVIA Technologies discusses how AI can advance trial execution and what stakeholders should be keeping top of mind when choosing technology vendors.

Breakout session at SCOPE Summit 2024 discusses the potential use of artificial intelligence to improve clinical trial strategy generation.

Adjusting to the changing dynamics of the clinical research associate role.

Phase II trial data show positive survival results for BXCL701 combined with Keytruda (pembrolizumab) to treat patients with metastatic small cell neuroendocrine prostate cancer.

Interactive panel at SCOPE discussed the potential of utilizing artificial intelligence in clinical trials.

Phase IIb B-Clear trial shows bepirovirsen reduced HBsAg levels and HBV DNA following 24 weeks of treatment in patients with chronic hepatitis B.

Two multicenter, randomized, double-blind, placebo-controlled clinical trials showed that 53.1% of patients administered Eohilia achieved histologic remission compared with 1% of patients administered placebo.

The DCT-driven evolution requires new levels of understanding and expertise.

Addressing challenges with eCOA at the site-level.

While many groups rely on manual chemistry processes, innovative platforms have emerged that allow these protocols to be executed on custom automation systems.